Intracavitary Immunotherapy and Chemotherapy for Upper Urinary Tract Cancer: Current Evidence

Reviews in Urology

Elena Tondelli¹  Augusto Maggioni⁵  Angelica Grasso⁵  Gabriele Cozzi⁵  Roberto Bianchi³  Nicola Macchione²  Carlo Marenghi⁴  Sara Melegari³  Marco Rosso⁵  Luca Carmignani⁴ 

[1] Università degli Studi di Milano, Urology Department, IRCCS S. Giuseppe Hospital, Milan, Italy;Università degli Studi di Milano, Urology Department, S. Paolo Hospital, Milan, Italy;Università degli Studi di Milano, Urology Department, European Institute of Oncology, Milan, Italy;Università degli Studi di Milano, Urology Department, IRCCS Policlinico San Donato,, San Donato Milanese, Italy;Università degli Studi di Milano, Urology Department, Fondazione IRCCS Ca’ Granda—Ospedale Maggiore Policlinico, Milan, Italy

关键词: Upper urinary tract;    Urothelial cell carcinoma;    Bacillus Calmette-Guérin;    Mitomycin C;    Chemotherapy;    Immunotherapy;   

DOI  :  

学科分类：基础医学

来源: MedReviews, LLC

【 摘 要 】

A review of the literature was performed to summarize current evidence regarding the efficacy of topical immunotherapy and chemotherapy for upper urinary tract urothelial cell carcinoma (UUT-UCC) in terms of post-treatment recurrence rates. A Medline database literature search was performed in March 2012 using the terms upper urinary tract, urothelial cancer, bacillus Calmette-Guérin (BCG), and mitomycin C. A total of 22 full-text articles were assessed for eligibility, and 19 studies reporting the outcomes of patients who underwent immunotherapy or chemotherapy with curative or adjuvant intent for UUT-UCC were chosen for quantitative analysis. Overall, the role of immunotherapy and chemotherapy for UUT-UCC is not firmly established. The most established practice is the treatment of carcinoma in situ (CIS) with BCG, even if a significant advantage has not yet been proven. The use of BCG as adjuvant therapy after complete resection of papillary UUT-UCC has been studied less extensively, even if recurrence rates are not significantly different than after the treatment of CIS. Only a few reports describe the use of mitomycin C, making it difficult to obtain significant evidence.

【 授权许可】

Unknown